Methods for stimulating hair growth by administering BMPs
First Claim
Patent Images
1. A method of treating a hair loss disorder comprising:
- (a) identifying a patient suffering from a hair loss disorder;
(b) administering a composition comprising a therapeutically effective amount of at least one BMP chosen from the group consisting of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, BMP-16, BMP-17, BMP-18, and MP52/GDF-5; and
(c) allowing the at least one active agent to promote hair growth.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods and compositions for stimulating hair growth and inhibiting immune system activity by administering BMPs are provided. The methods and compositions can be used for treating or preventing disorders resulting in loss of hair, as well as a wide range of autoimmune disorders.
-
Citations
31 Claims
-
1. A method of treating a hair loss disorder comprising:
-
(a) identifying a patient suffering from a hair loss disorder;
(b) administering a composition comprising a therapeutically effective amount of at least one BMP chosen from the group consisting of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, BMP-16, BMP-17, BMP-18, and MP52/GDF-5; and
(c) allowing the at least one active agent to promote hair growth. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. A method of treating a hair loss disorder comprising:
-
(a) identifying a patient suffering from a hair loss disorder;
(b) administering a composition comprising a therapeutically effective amount of at least one BMP chosen from the group consisting of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, BMP-16, BMP-17, BMP-18, and MP52/GDF-5;
(c) administering a therapeutically effective amount of at least one compound chosen from the group consisting of prednisone, dexamethisone, hydrocortisone, cyclosporin A, pimecrolimus, tacrolimus, minoxidil, and finasteride; and
(d) allowing the active agents to promote hair growth.
-
-
15. A method of treating an autoimmune disorder comprising:
-
(a) identifying a patient suffering from an autoimmune disorder;
(b) administering a composition comprising a therapeutically effective amount of at least one BMP chosen from the group consisting of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, BMP-16, BMP-17, BMP-18, and MP52/GDF-5; and
(c) allowing the at least one BMP to inhibit immune system activity. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)
-
-
28. A method of treating an autoimmune disorder comprising:
-
(a) identifying a patient suffering from an autoimmune disorder;
(b) administering a composition comprising a therapeutically effective amount of at least one BMP chosen from the group consisting of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, BMP-16, BMP-17, BMP-18, and MP52/GDF-5;
(c) administering a therapeutically effective amount of at least one compound chosen from the group consisting of cyclosporin A, pimecrolimus, tacrolimus, azathioprine, mycophenolate mofetil, rapamycin, CCI-779, methotrexate, leflunomide, interferon-β
, copaxone, budenoside, epidermal growth factor, sulfasalazine, 6-mercaptopurine, azathioprine, metronidazole, mesalamine, olsalazine, ciprofloxacin, and lignocaine; and
(d) allowing the BMPs to inhibit immune system activity.
-
-
29. A pharmaceutical composition comprising:
-
(a) at least one BMP chosen from the group consisting of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, BMP-16, BMP-17, BMP-18, and MP52/GDF-5;
(b) a sterile solution of 0.5% sucrose, 2.5% glycine, 5 mM L-glutamic acid, 5 mM NaCl, and 0.01% polysorbate 80, at pH 4.50.
-
-
30. A pharmaceutical composition for promoting hair growth comprising:
-
(a) at least one BMP chosen from the group consisting of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, BMP-16, BMP-17, BMP-18, and MP52/GDF-5; and
(b) at least one compound chosen from the group consisting of prednisone, dexamethisone, hydrocortisone, cyclosporin A, pimecrolimus, tacrolimus, minoxidil, and finasteride.
-
-
31. A pharmaceutical composition for inhibiting immune system activity comprising:
-
(a) at least one BMP chosen from the group consisting of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, BMP-16, BMP-17, BMP-18, and MP52/GDF-5, (b) and at least one compound chosen from the group consisting of cyclosporin A, pimecrolimus, tacrolimus, azathioprine, mycophenolate mofetil, rapamycin, CCI-779, methotrexate, leflunomide, interferon-β
, copaxone, budenoside, epidermal growth factor, sulfasalazine, 6-mercaptopurine, azathioprine, metronidazole, mesalamine, olsalazine, ciprofloxacin, and lignocaine.
-
Specification